Benefits of Ramucirumab for patients with high AFP liver cancer

Share This Post

Liver cancer

Liver cancer is a typical vascular-rich tumor, and tumor blood vessels play a very important role in the development of liver cancer. Therefore, the current targeted therapy of liver cancer is carried out around anti-angiogenesis. Anti-angiogenesis therapy is a very important strategy in the clinical practice of liver cancer.


The REACH-2 trial is carried out on the basis of the REACH trial. The Chinese American scholar Professor Andrew X. Zhu of the Massachusetts Hospital affiliated to Harvard University in the United States serves as the global PI. For the liver cancer patients who failed to treat Sorafenib, the comparison Ramucirumab differed from placebo in the efficacy of second-line treatment, but the trial did not achieve the expected results. But its subgroup analysis shows that patients with AFP (alpha-fetoprotein) over 400 ng / ml can benefit from Ramucirumab treatment. Therefore, Professor Zhu led the REACH-2 trial and found that Ramucirumab benefits patients both in overall survival and progression-free survival time compared with placebo. This test has epoch-making significance, and it further proves that in the second-line treatment of liver cancer, anti-angiogenesis treatment with macromolecular monoclonal antibodies can achieve clinically meaningful survival benefits.

At present, oxaliplatin has been approved as a standard treatment plan in both domestic and European countries. For small-molecule targeted drugs, sorafenib and lenvatinib can be used for first-line therapy, and regorafenib and carbotinib are used for second-line therapy. For large-molecule drugs, Nivolumab and Ramucirumab are both Choose drugs.

In addition, many liver cancer patients have hepatitis, and the same patient, the same organ at the same time, there are two completely different diseases. One type is basic liver disease, including hepatitis, whether it is viral hepatitis, or alcoholic liver disease, fatty liver, cirrhosis, there may be abnormal liver function and other complications. The second category is highly advanced liver cancer. These two diseases affect each other and form a vicious circle. Therefore, it is necessary to give due consideration to the diagnosis and treatment process, to prevent the loss of each other. In recent years, it has been advocated that antiviral treatment and liver protection treatment be carried out simultaneously. This is another progress made in the treatment of liver cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy